Successful use of recombinant human erythropoietin in a pregnant woman with lupus nephritis.
Recombinant human erythropoietin (r-HuEPO) is broadly accepted as treatment for anemia in dialysis and nondialysis patients with chronic renal failure, but data regarding the safety and efficacy of this drug in pregnancy are limited. Maternal and fetal problems have been reported to be associated with anemia during pregnancy. On the other hand, anemia is a frequent feature of systemic lupus erythematosus. We report the successful use of r-HuEPO in a young woman with lupus nephritis complicated by severe anemia during pregnancy. Additional studies should be encouraged to confirm the safety of r-HuEPO therapy during pregnancy.
D000328:Adult; D000740:Anemia / Q000097:blood / Q000150:complications / Q000628:therapy*; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006801:Humans; D008181:Lupus Nephritis / Q000150:complications*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy*; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use
D011994:Recombinant Proteins; D004921:Erythropoietin